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Abstract 
Dysregulation of the immune response to microbiota is associated with inflammatory 
bowel disease (IBD), which can trigger intestinal fibrosis. MyD88 is a key component 
of microbiota signalling but its influence on intestinal fibrosis has not been clarified. 
Small bowel resections from donor-mice were transplanted subcutaneously into the 
neck of recipients C57BL/6 B6-MyD88tm1 Aki (MyD88-/-) and C57BL/6-Tg(UBC-green 
fluorescence protein (GFP))30Scha/J (GFP-Tg). Grafts were explanted up to 21 days 
after transplantation. Collagen layer thickness was determined using Sirius Red 
stained slides. 
In the mouse model of fibrosis collagen deposition and transforming growth factor-beta 
1 (TGF-β1) expression was equal in MyD88+/+ and MyD88-/-, indicating that MyD88 
was not essential for fibrogenesis. Matrix metalloproteinase (Mmp)9 expression was 
significantly decreased in grafts transplanted into MyD88-/- recipients compared to 
MyD88+/+ recipients (0.2 ± 0.1 vs. 153.0 ± 23.1, respectively, p < 0.05), similarly 
recruitment of neutrophils was significantly reduced (16.3 ± 4.5 vs. 25.4 ± 3.1, 
respectively, p < 0.05). 
Development of intestinal fibrosis appears to be independent of MyD88 signalling 
indicating a minor role of bacterial wall compounds in the process which is in contrast 
to published concepts and theories. Development of fibrosis appears to be uncoupled 
from acute inflammation.   
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Introduction 
Innate immunity plays a pivotal role in IBD, with its two entities Crohn’s disease (CD) 
and ulcerative colitis (UC) 1. In IBD, the intestinal microbiota leads to a response by 
the innate immune system causing inflammation. Dedicated extracellular and 
intracellular pattern recognition receptors, such as ten different Toll-like receptors 
(TLRs) and NOD-like receptors with at least 23 variants in the human genome, are 
responsible for sensing local microbiota 2. TLR stimulation triggers an intracellular 
cascade via the cytoplasmic Toll/interleukin-1 (IL-1) receptor (TIR) signalling domain. 
TLR signalling depends critically on a total of four adaptor proteins — MyD88, TIR 
adaptor protein (TIRAP, also called MAL), (TIR)-containing adapter molecule 1 
(TICAM1, also called TRIF), and TICAM2 (also called TRAM) — that directly bind to 
activated TLRs and recruit downstream signalling components 3. MyD88 is a TIR 
domain-containing adaptor protein for the induction of inflammatory cytokines triggered 
by all TLRs with the exception of TLR3 3 and is expressed in a variety of cells 4-6. 
Signalling via MyD88 leads to the activation of downstream nuclear transcription 
factors such as nuclear factor-kB (NF-kB), cyclic AMP response element-binding 
protein and AP-1 ensuring the production of pro-inflammatory cytokines such as tumor 
necrosis factor (TNF) and IL-1, chemokines and other soluble mediators with 
subsequent inflammation and leukocyte accumulation 2. 
Dysregulated microbiota signalling is associated with IBD pathophysiology. 
Epidemiological studies of the pattern recognition receptors upstream of MyD88 clearly 
show an association between TLR4 7, TLR5 8 and TLR9 9 polymorphisms and 
susceptibility to IBD. TLR1, TLR2 and TLR6 variants were found to be associated with 
disease phenotypes 10. A genetic variant in the gene encoding TIRAP, necessary to 
recruit MyD88 to TLR2 and TLR4 has an effect on the risk of IBD 11. Equally, for 
components downstream of MyD88 studies show an association between signalling 
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dysfunction and IBD 12,13. MyD88 can be viewed as a focal point for microbiota 
signalling involved in the signal transduction of almost all TLRs and causing 
inflammation. Studies have identified patients with mutations in MYD88 that abolish 
protein production and result in a primary immunodeficiency syndrome characterized 
by greater susceptibility to pyogenic bacteria 14-16. Three different autosomal recessive 
mutations have been described in MYD88-deficient patients suffering from recurrent 
infections with pyogenic bacteria. Life-threatening infections in subjects with defective 
MyD88 first occur during early infancy 14.  
Thus, one would also expect an association between MyD88 polymorphisms or its 
dysregulated expression and a susceptibility to IBD. A total of 163 IBD loci that meet 
genome-wide significance thresholds were found by analysis of data from 15 genome-
wide association studies of CD and UC combined with Immunochip validation 17. 
However, disease-associated MyD88 polymorphisms were not described. Further 
studies showed that the MyD88 polymorphism rs7744 is closely associated with the 
development of UC and that this polymorphism may be linked with the response to UC 
therapeutic approaches 18. The function of rs7744 has not been clearly identified, 
although minor allele variants is thought to lead to an overexpression of the MyD88 
protein 18, considering the increased mRNA and protein levels of MyD88 in UC patients 
19. 
Fibrosis is increasingly being recognised as an important cause of morbidity and 
mortality in IBD. While the triggering of fibrosis seems to require inflammation as a 
prerequisite step, the mechanisms involved in the progression of fibrogenesis may be 
distinct. There is evidence that intestinal fibrogenesis after being initiated is - at least 
to some extent - a self-perpetuating process 20. Administration of potent anti-
inflammatory agents effectively treats inflammatory flares, but at present there is no 
specific treatment option for patients with recurrent intestinal fibrosis 21,22. Notable 
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progress has been made in elucidating therapeutic targets to tackle the inflammatory 
component of IBD, but the incidence of strictures and of subsequent surgical 
interventions remains relatively unchanged 23.  
In this current study we describe the role of the MyD88-dependent innate immunity 
pathway in the fibrogenic process. We applied the rapid and reliable heterotopic 
transplantation model of intestinal fibrosis 24 to MyD88-deficient mice. Our data 
suggests that the development and progression of fibrosis in the intestine is not 
dependent on MyD88 signalling but alludes to the presence of alternative pathways 
which contribute to this process. This suggests that anti-inflammatory agents – 
although essential to treat inflammatory flares – are not a sufficient treatment option 
against IBD-associated fibrosis. 
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Materials and methods 
All experiments were performed in accordance with relevant guidelines and 
regulations. 
Animals 
C57BL/6 B6-MyD88tm1 Aki (MyD88-/-) and C57BL/6-Tg(UBC-green fluorescence 
protein (GFP))30Scha/J (GFP-Tg) mice weighing 20g were obtained from Jackson 
Laboratories and bred locally. The animals received standard laboratory mouse food 
and water ad libitum. They were housed under specific pathogen-free conditions in 
individually ventilated cages. The experimental protocol was approved by the local 
Animal Care Committee of the University of Zurich (registration numbers 114/2011 and 
ZH183/2014). 
 
Heterotopic intestinal transplant model 
The heterotopic mouse intestinal transplant model is an adaption of the transplantation 
model of intestinal fibrosis in rats. Both have been previously described in detail 24,25. 
In short, donor small bowel was resected and transplanted subcutaneously into the 
neck of recipient animals. Intestinal grafts were explanted up to 21 days after 
transplantation. At explantation, each graft was divided into three equal segments. One 
segment was fixed in 4% formalin and prepared for histopathological assessment. The 
other segments were snap frozen in liquid nitrogen and stored at -80°C until RNA 
extraction.  
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RNA isolation, cDNA synthesis and real-time PCR 
For isolation of total RNA, lysis buffer from the RNeasy® kit (Qiagen, Hilden, Germany) 
was added to snap frozen resections. Samples were shredded in M tubes (# 130-093-
236, Miltenyi Biotec) in a gentle MACSTM dissociator (Miltenyi Biotec). Total RNA was 
prepared according to the manufacturer’s protocol and stored at −80°C. Quality of total 
RNA was controlled with the Agilent 2100 expert EukaryoteTotal RNA Nano Assay. 
Only RNA with a RNA integrity number > 6 was used for analysis. The isolated RNA 
was reverse-transcribed using a Reverse Transcription System (Applied Biosystems). 
Quantitative mRNA analysis by real-time PCR was performed using Taqman® gene 
Expression Assays for mouse collagen type I alpha 1 (Col1a1) Mm00801666_g1, TGF-
β1 Mm01178820_m1, MMP-9 Mm00442991_m1, tissue inhibitor of matrix 
metalloproteinase 1 (TIMP-1) Mm00441818_m1, hypoxia inducible factor 1 alpha 
subunit (HIF-1α) Mm01283760_m1 and GAPDH # 4352339E TaqMan® Gene 
Expression Assays. The relative cDNA concentration for the gene of interest was 
calculated using the ddCt-method. 
 
Immunohistochemistry (IHC) 
TGF-1 was stained with a rabbit polyclonal antibody from Santa Cruz Biotechnology 
Inc. (#sc-146, dilution 1:200, immunstainer Leica Bond III Stainer, pretreatment: Bond 
Epitop Retrival Buffer 2 for 20 min., detections kit: Bond Polymer Refine Detections 
Kit, all reagents from Bond Leica). The sections were examined with the Imager Z2 
microscope (Zeiss) and AxioVision software (Zeiss).  
Sirius Red-stained slides were analyzed by bright-field microscopy with an additional 
polarizing filter. Under polarized light Sirius Red-stained collagen assumes a palette of 
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colors ranging from green to red based on the fibrotic maturation process. Collagen 
layer thickness was determined by an investigator blinded to the experiment. 
Thickness was measured in at least eight places in representative areas at 10-fold 
magnification. Similarly slides were stained with Elastica van Gieson and analyzed 
using transmission light microscopy. Collagen layer thickness was determined as 
previously described for Sirius Red staining. 
 
Statistical analysis 
Statistical analysis for real time PCR and collagen layer thickness was performed using 
Kruskal-Wallis one way analysis of variance on ranks, all pairwise multiple comparison 
procedures, Dunn's method. Comparison between genotypes was performed using the 
Mann-Whitney-Test for each time point. Differences were considered significant at a 
p-value of < 0.05 (*) and highly significant at a p-value of < 0.01 (**) and p-value of < 
0.001 (***). 
 
Ethical considerations 
The experimental protocol for animals was approved by the local Animal Care 
Committee of the University of Zurich (registration numbers 114/2011 and 
ZH183/2014).   
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Results 
 
Development of intestinal fibrosis is not prevented in grafts extracted from GFP-
Tg donor animals and transplanted into MyD88-/- recipients. 
To determine the relevance of MyD88 in the development of fibrosis, MyD88-/- and 
GFP-Tg mice were used as both donors and recipients for isogeneic transplantation in 
our heterotopic animal model of intestinal fibrosis. The presence of endogenous GFP 
in GFP-Tg donor or recipient mice allowed for a genotype-specific staining. Body 
weight remained unchanged in both MyD88-/- and GFP-Tg recipients (not shown). 
Grafts were explanted up to 21 days after transplantation as indicated. 26 isogeneic 
transplants (GFP-Tg into GFP-Tg mice), 58 isogeneic transplants (GFP-Tg into 
MyD88-/- mice) and 47 isogeneic transplants (MyD88-/- into GFP-Tg mice) were 
performed. Of 131 transplants histologically evaluable tissue was recovered from all 
but 7 grafts. To compare grafts with non-transplanted tissue 28 small bowel resections 
were extracted from GFP-Tg mice and six small bowel resections were extracted from 
MyD88-/- mice. 
Exaggerated collagen deposition is a histologic and molecular hallmark of human 
intestinal fibrosis, therefore Col1a1 mRNA expression was analyzed by real-time PCR 
(Figure 1 A). Col1a1 mRNA increased in a time-dependent manner. Col1a1 mRNA 
expression was significantly increased 5 days after transplantation in isogeneic 
transplants of GFP-Tg into GFP-Tg mice, GFP-Tg into MyD88-/- mice and MyD88-/- into 
GFP-Tg mice compared to freshly isolated small intestine (Figure 1A, 177.3 ± 86.09 
vs. 209.6 ± 73.62 vs. 1.00 ± 0.11, p < 0.01 (**) and 198.9 ± 52.6 vs. 0.86 ± 0.15, p < 
0.05 (*) respectively, n = as indicated). The development of Col1a1 mRNA expression 
curves over time is similar in grafts of both genotypes. 
C. Lutz and B. Weder et al. 
 10 
The development of intestinal fibrosis after heterotopic transplantation was also 
observed in histological cross sections. Collagen production and deposition in the 
intestinal transplants was determined by Sirius red staining under transmission and 
polarizing light microscopy (Figure 1B). In Sirius red-stained histological cross-sections 
freshly isolated small intestine was characterized by an open lumen and distinctive 
epithelial crypts (Figure 1B). At day 7 after transplantation the lumen of intestinal grafts 
was obstructed by granulation tissue and fibrotic material. Freshly isolated small 
intestine was characterized by mostly long-chained collagen (red stain) adjacent to the 
submucosa. The presence of short-chained collagen (green and yellow stain) 
increased continuously in the submucosa and in the luminal occlusion after 
transplantation. Loss of epithelial structures and luminal occlusion was observed 
irrespective of the genotype of donor and recipient mice. Time dependent increase in 
collagen was also confirmed by Elastica van Gieson (EvG) staining (Supplementary 
Figure 1). 
The collagen layer thickness in harvested grafts was significantly increased in 
comparison to the collagen layer thickness in freshly isolated small intestine (Figure 
1C, p < 0.01 (**), calculated from n = number of grafts as indicated). Collagen layer 
thickness is comparable between grafts in both MyD88-/- and GFP-Tg recipients over 
time. 
 
Myd88 is not required for an increase in Hif1α expression after heterotopic small 
bowel transplantation. 
MyD88 signaling regulates Hif-1α expression 26. Therefore Hif1α mRNA expression 
was analyzed by real-time PCR to determine hypoxia-mediated signalling (Figure 2). 
Surprisingly Hif1α mRNA was unchanged for at least 48 hours in grafts of both 
genotypes. This was followed by a significantly increased Hif1α mRNA expression after 
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4 days in isogeneic transplants of both GFP-Tg into MyD88-/- mice as well as MyD88-
/- into GFP-Tg mice compared to freshly isolated small intestine (Figure 2, 2.90 ± 0.89, 
vs. 1.00 ± 0.01 and 3.60 ± 0.52 vs. 0.77 ± 0.23, respectively, *p < 0.05, n = 3 each 
column). The development of Hif1α mRNA expression over time is similar in grafts of 
both genotypes.  
Previously, we could show that macroscopically visible blood vessels from the 
surrounding tissue extend towards the graft where they form a dense vascular network. 
In this study we determined the origin of the lumen-obstructing cells in isogeneic 
transplants (MyD88-/- into GFP-Tg mice). As expected, the freshly isolated intestinal 
resections from MyD88-/- mice are negative for GFP staining (Supplementary Figure 2 
A and B). An increase in infiltration of stained GFP cells ensued in a time-dependent 
manner. Initially, red-stained cells were visible exclusively in the submucosa and 
seemed to accumulate along the collagen layer. Subsequent time-points showed 
progressive infiltration along the crypts and into the lumen. As seen in GFP staining, 
the infiltrating cells frequently enter the graft not in a diffuse, but rather in a more 
localized fashion, with specific points of access forming along the graft wall 
(Supplementary Figure 2 B). They then pour across the tissue and into the lumen 
contributing to the total occlusion of the graft. Seven days after transplantation GFP 
positive blood vessels appear within the GFP negative donor tissue (Supplementary 
Figure 2 C). This result demonstrates an increased infiltration to the graft via blood 
vessels irrespective of MyD88-driven signalling. 
 
Induction Tgf1 mRNA expression during fibrosis is independent from Myd88  
To further substantiate that fibrosis evolves independently from MyD88 signalling, 
expression of Tgf was analyzed. Tgf1 mRNA expression was increased in a time-
dependent manner (Figure 3 A). Tgf mRNA expression was significantly increased 
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5 days after transplantation in isogeneic transplants of both GFP-Tg into GFP-Tg mice, 
in isogeneic transplants of both GFP-Tg into MyD88-/- mice and MyD88-/- into GFP-Tg 
mice compared to freshly isolated small intestine (5.20 ± 2.1, vs. 1.00 ± 0.9, 3.61 ± 
0.98, vs. 1.00 ± 0.9 and 4.00 ± 0.73 vs. 1.18 ± 0.21 respectively, p < 0.05 (*), n = as 
indicated). Similar results were obtained 21 days after transplantation compared to 
freshly isolated small intestine (GFP-Tg into GFP-Tg mice: 6.20 ± 1.3, vs. 1.00 ± 0.9, 
GFP-Tg into MyD88-/- mice: 5.17 ± 1.33, vs. 1.00 ± 0.9 and MyD88-/- into GFP-Tg mice: 
4.99 ± 1.42 vs. 1.18 ± 0.21 respectively, p < 0.05 (*), n = as indicated). Tgf1 mRNA 
expression was similar between grafts of both genotypes over time. TGF-1 was also 
detected by IHC along the crypt villus axis in mouse intestinal epithelial cells in freshly 
isolated intestine (Figure 3B). No TGF-1 was detected in the lamina propria. Intense 
staining for TGF was found in the luminal occlusion from day 5 to day 21 in isografts 
of both MyD88-/- and GFP-Tg recipients.  
 
MyD88 deficiency reduces intestinal inflammation but not the development of 
intestinal fibrosis  
MyD88-signalling is an inducer of MMP-9 expression 27,28. As MMPs are involved in 
mucosal fibrosis we determined the expression of tissue remodeling protease MMP-9 
and the tissue inhibitor of metalloproteinases TIMP-1 in intestinal transplants by real-
time PCR. Mmp9 mRNA expression was increased in a time-dependent manner and 
was significantly increased in grafts from both GFP-Tg donors transplanted into GFP-
Tg recipients and MyD88-/- donors transplanted into GFP-Tg recipients at day 14 
compared to grafts from GFP-Tg donors transplanted into MyD88-/- recipients at day 
14 (Figure 4 A, 133.0 ± 24.0 and 153.0 ± 23.1 vs. 0.15 ± 0.10, respectively, p < 0.05 
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(*), n = 3 in each column). In contrast, increase of TIMP-1 mRNA expression is similar 
between grafts of both genotypes over time (Figure 4 B, n = 3 each column). 
As MMP-9 is produced by neutrophils in large quantities we determined if Mmp9 mRNA 
expression coincided with the accumulation of Ly-6G positive neutrophils and 
performed the relevant immunohistochemistry. As expected, Ly-6G staining was more 
pronounced in grafts from MyD88-/- donors transplanted into GFP-Tg recipients at day 
7 and 14 compared to grafts from GFP-Tg donors transplanted into MyD88-/- recipients 
at day 7 (Figure 4 C) and 14 (Supplementary figure 3). A significantly increased number 
of Ly-6G positive neutrophils was determined in grafts from MyD88-/- donors 
transplanted into GFP-Tg recipients at day 7 and 14 compared to freshly isolated small 
bowel (Figure 4 C, 25.4 ± 3.1 and 24.6 ± 10.8 vs. 0.3 ± 0.7, respectively, *p < 0.05, n = 
as indicated). Further a significantly reduced number of neutrophils in grafts from GFP-
Tg donors transplanted into MyD88-/- recipients at day 7 and 14 compared to grafts 
from MyD88-/- donors transplanted into GFP-Tg recipients confirmed the hypothesis 
that large quantities of MMP-9 were produced by neutrophils (Figure 4 C, 16.3 ± 4.5 
vs. 25.4 ± 3.1 and 9.1 ± 5.7 vs. 24.6 ± 10.8, respectively, *p < 0.05, n = as indicated). 
Accumulation of neutrophils was therefore significantly increased in heterotopic 
intestinal grafts transplanted into mice capable of MyD88 signalling compared to 
recipients deficient in MyD88 signalling. Therefore, MyD88 deficiency reduces 
intestinal inflammation, at least with respect to Mmp9 expression and neutrophil 
infiltration whereas development of fibrosis is similar in grafts of both MyD88 deficient 
and wildtype mice. 
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Discussion 
In this study we investigated the role of MyD88 in the development and progression of 
fibrosis in an animal model of intestinal fibrosis. All hallmarks of intestinal fibrosis were 
similar in wildtype and MyD88-/- animals. Specifically, we found increased collagen 
expression, which intensified over time, virtually identical in both MyD88-/- and GFP-Tg 
grafts. Increased collagen deposition in the intestinal wall over time was detected by 
histological analysis and confirmed the real time PCR data. EvG and Sirius red staining 
demonstrated an identical network of progressively shorter-chain collagen fibrils 
accumulating in an IBD-mimicking fashion in grafts from both genotypes. We also 
found an increase in Tgfβ1 expression over time in both grafts. Histological staining 
confirmed the increase in TGF-β1 in the obliterated lumen and the surrounding tissue. 
In addition, real-time PCR revealed a time-dependent increase of Timp1 mRNA in both 
grafts.  
In contrast, pronounced differences between wildtype and MyD88-/- animals could also 
be observed. While Mmp9 expression was increased upon development of fibrosis we 
did observe a significant difference between the grafts from both genotypes. MyD88-
signalling is a potent inducer of MMP-9 expression 27,28. Likewise, GFP-Tg grafts 
transplanted into MyD88-/- recipients yielded significantly lower expression levels than 
the MyD88-/- grafts in GFP-Tg recipients. MMP-9 is produced plentifully by neutrophils 
29, suggesting that the recipient cells infiltrating the transplant are mainly responsible 
for the production of this mediator. Histological staining confirms a significantly 
increased number of Ly-6G positive neutrophils in the obliterated lumen in grafts from 
MyD88-/- donors transplanted into GFP-Tg recipients as compared to grafts from GFP-
Tg donors transplanted into MyD88-/- recipients. MMP-9 is considered as a critical 
component of intestinal inflammation in IBD, but less is known concerning the role of 
MMP-9 in penetrating or stricturing CD. Recently, we have generated an anti-MMP-9 
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antibody, CALY-001, and have evaluated its efficacy in fibrogenesis. We showed that 
inhibiting MMP-9 significantly reduces collagen deposition and intestinal tissue 
remodelling 30. This anti-fibrotic effect, associated with the anti-inflammatory effect of 
MMP-9 inhibitor described in the DSS-colitis model by Marshall and colleagues using 
an alternative anti-MMP-9 antibody, AB-0046 31, supports the development of an anti-
MMP-9 antibody in patients with penetrating CD. 
Several animal models for the study of intestinal fibrosis have been proposed 32. All of 
them have some advantages as well as disadvantages and none of them really 
resembles intestinal fibrosis of CD patients. Intramural injection of peptide glycan–
polysaccharide complex at laparotomy has been shown to cause intestinal fibrosis in 
rats with immunopathological features resembling CD 33. In this model, bacterial cell 
wall polymers were shown to stimulate collagen and TGF-b1 expression in intestinal 
myofibroblasts 34. In the trinitrobenzene sulfonic acid–induced model of colitis, rats 
develop colonic fibrosis and stricture formation, but this has not yet been well 
characterized 35. Our animal model of intestinal fibrosis may have its own 
limitations.The observed increase in neutrophils in the heterotopic transplantation 
model may be affected by immune response to intestinal grafts, rejection, ischemia or 
hypoxia which contributes to fibrosis in the animal model but not necessarily to fibrosis 
in IBD patients. 
Differences in the microbiome are likely to influence development of intestinal fibrosis. 
The intestinal microbiota that lead to a response by the innate immune system in IBD 
cause inflammation and may trigger fibrogenesis. However, there are conflicting 
reports on the importance of the MyD88-dependent signalling in the development of 
intestinal fibrosis. S. typhimurium ranges among the most prevalent agents of 
foodborne diseases and provokes severe inflammatory responses and thus may 
initiate fibrosis. Infection studies with streptomycin pretreated mice showed evidence 
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for MyD88-dependent and MyD88-independent pathways in S. typhimurium colitis 36. 
S. typhimurium was shown to efficiently colonize the cecal lumen and to cause the 
same level of inflammation in both MyD88+/+ and MyD88-/- 36,37. S. typhimurium can 
efficiently induce inflammation even in the absence of MyD88 signalling. Intestinal 
dendritic cells are believed to sample and present not only S. typhimurium but all 
commensal bacteria to the gut-associated immune system. MyD88 signaling in 
mucosal dendritic cells is not required for induction of colitis by S. typhimurium 38. In 
contrast, using a less virulent S. typhimurium strain in infection studies MyD88-/- mice 
displayed a decrease in collagen and mucosal inflammation in ceca compared to 
wildtype mice 37. Submucosal inflammation and fibroblast accumulation was similar in 
the infected MyD88-/- and wildtype mice 37 and the authors conclude that fibrosis is not 
simply a secondary effect of local inflammation and tissue damage. Studies where S. 
typhimurium infection in mice was eradicated with antibiotics showed evidence that 
fibrogenesis is preceded by inflammation but eradication of the inflammatory stimulus 
represses inflammation without preventing fibrosis 20. This suggests that intestinal 
fibrosis does not require persistent microbal stimulation and could be independent from 
the MyD88 pathways from a certain time point onwards.  
There are also conflicting reports on the importance of the MyD88-dependent 
signalling in the development of fibrosis in other organs. Kidney fibrosis studies using 
various murine models have shown MyD88 to be a key component of this disease, 
whereby its absence coincided with reduced inflammation and attenuated collagen 
deposition 39,40. MyD88-activation was linked with a shift in the immune response 
towards T helper type 2 differentiation and M2 polarisation of macrophages 39. This 
pattern has previously been implicated in the development and progression of fibrosis 
41,42. Confirmatively, MyD88 signalling was found to be essential for the inflammation 
and fibrosis in a bleomycin-induced model of pulmonary disease 43. The TLR4-
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triggered MyD88 pathway was found to be crucial to hepatic fibrosis by potentiating 
pro-fibrotic TGF-β1 signalling 44. In contrast, in other studies using different models of 
fibrosis MyD88 signalling is less relevant for the development and progression of 
fibrosis. For instance, Leptospira interrogans induces fibrosis in mouse kidney in a 
MyD88-independent fashion 45. Similarly, a recent study showed that MyD88, while 
relevant for the inflammatory process, plays only a minor role in a silica model of lung 
fibrosis 46. Critically, MyD88-deficient mice presented a pronounced accumulation of 
pro-fibrotic cytokines and did not manifest a tempering of collagen deposition. 
TLRs and NOD-like receptors are responsible for sensing local microbiota 2. TLR are 
not only expressed in macrophages, dendritic cells and intestinal epithelial cells but 
also in primary colonic myofibroblasts 47, one of the main producers of extracellular 
matrix components that are deposited during fibrosis. In mice, MyD88 is essential for 
the inflammatory responses mediated by almost all TLR family members 48 as MyD88-
/- show no responses to the TLR2 ligands peptidoglycan and lipoprotein 49,50, to the 
TLR4 ligand lipopolysaccharide (LPS) 51, to the TLR5 ligand flagellin 52, to the TLR7 
ligand imidazoquinoline 53 and to the TLR9 ligand CpG DNA 54,55. On one hand MyD88 
signalling is required to limit the bacterial burden and mice with a Myd88-deficiency 
have increased susceptibility to bacterial and viral infections. On the other hand 
MyD88-independent TLR signaling pathways have also been identified 56-58.  
Furthermore wound healing is impaired in MyD88-deficient mice. Adequate wound 
healing is the result of an exquisite physiological balance between multiple pro- and 
anti-fibrotic stimuli on extracellular matrix-producing cells 59-62. Excessive tissue repair 
promotes fibrosis and impairs gastrointestinal function and is a common clinical 
problem in patients with IBD.  
The data presented here suggest that although inflammation is reduced by MyD88 
deficiency, the development of intestinal fibrosis is uncoupled from MyD88 signalling. 
C. Lutz and B. Weder et al. 
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MyD88 is not the only adaptor protein involved in Toll/IL-1 receptor family signalling. 
Stimulation of TLR3 and TLR4 in the absence of MyD88 still leads to the activation of 
NF-kB, albeit with delayed kinetics 51. Interestingly, TLR4 polymorphisms have been 
associated with an increased susceptibility for IBD 63,64. The MyD88-independent TLR4 
response occurs via the adaptor TIR domain-containing adaptor inducing IFN-beta 
(TRIF) which then triggers the interferon regulatory factor 3 (IRF3) 57,65 or NF-kB via 
RIP 66. Furthermore, TLRs are not the only pattern recognition receptors involved in 
the innate immune response. Intracellular NOD/CARD-like receptors are also able to 
bind PAMPs 67 and have been shown, in the case of NOD2/CARD15, to be strictly 
linked to CD 68. However, even considering the presence of these alternative 
pathways, the acute inflammatory response will be strongly reduced without a 
functional MyD88, as exemplified by a strongly reduced accumulation of neutrophils in 
our experiments. Development of fibrosis thus appears to be uncoupled from 
inflammation, contradicting published concepts and theories. This suggests that anti-
inflammatory agents – although essential to treat inflammatory flares – are not a 
sufficient treatment option against IBD associated fibrosis. 
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Figure legends 
 
Figure 1: Development of intestinal fibrosis is not prevented in grafts extracted 
from GFP-Tg donor animals and transplanted into MyD88-/- recipients. (A) Col1a1 
mRNA expression is significantly increased over time compared to freshly isolated 
intestine (p < 0.05 (*), p < 0.01(**), error bars = SEM, n = as indicated). (B) Sirius Red 
staining. Transmission light showed increased collagen layer thickness in grafts at day 
seven in comparison to freshly isolated intestine. Polarizing light microscopy confirmed 
increased collagen layer thickness at day seven. Representative figures from n = 3. 
(C) Thickness was calculated from at least eight places in representative areas at 10-
fold magnification for each single graft. Collagen layer thickness increased significantly 
in grafts over time. Mean value and SEM is shown (p < 0.01 (**), n = 8 – 16 for each 
column).  
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Figure 2: Myd88 is not required for an increase in Hif1α expression after 
heterotopic small bowel transplantation. Real time PCR confirmed significant 
increase of Hif1α expression over time (p < 0.05 (*), n = as indicated). Error bars = 
SEM.  
 
Figure 3: Induction of TGF-1 during fibrosis is independent from Myd88. (A) Real 
time PCR confirmed significant increase of Tgfβ1 expression over time (p < 0.05 (*), 
error bars = SEM, n = as indicated). Error bars = SEM. (B) IHC. In grafts a pronounced 
TGF-β1 staining (DAB, brown) over time was detected. Representative figures from n 
= 3. 
 
Figure 4: MyD88 deficiency reduces intestinal inflammation but not the 
development of intestinal fibrosis. (A) Significant increase of Mmp9 mRNA 
expression in grafts isolated from GFP-Tg recipients at day 14 in comparison to freshly 
isolated intestine. Mmp9 mRNA expression in grafts from MyD88-/- recipients remained 
unchanged over time (p < 0.05 (*), error bars = SEM, n = 3 each column). (B) Timp1 
mRNA expression remained identical over time in both grafts from GFP-Tg and MyD88-
/- recipients (n = 3 each column). (C) IHC revealed an increase in Ly-6G+ neutrophils 
in grafts extracted from both GFP-Tg and MyD88-/- donor animals compared to freshly 
isolated small intestine. The number of Ly-6G positive cells (yellow crosses) was 
significantly increased in grafts extracted from GFP-Tg (p < 0.05 (*), Kruskal-Wallis 
One Way Analysis of Variance on Ranks, All Pairwise Multiple Comparison 
Procedures, Dunn's Method). The number of Ly-6G positive neutrophils was calculated 
from at least four places in representative areas at 20-fold magnification. Mean value 
und standard deviation is shown. n = 4 – 7 as indicated. 
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